Reduzierte Gewinnaussichten und Marktreaktion Novo Nordisk hat am Mittwoch seine Gewinnaussichten für das Gesamtjahr gekürzt, nachdem es schwächer als erwartete Quartalszahlen veröffentlichte. Ein wichtiger Faktor beläuft sich dabei auf dem beliebten Gewichtsverlust-Medikament Wegovy . Dies hat bei den Investoren Sorgen über die Konkurrenz wie zum Beispiel Eli Lilly erregt. Die Ergebnisse beenden eine Serie positiver…
| Cookie | Dauer | Beschreibung |
|---|---|---|
| cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
